FAAH

FAAH-IN-8 is a competitive inhibitor of fatty acid amide hydrolase (FAAH), exhibiting an IC50 value of 6.7 nM and a Ki value of 5 nM. This compound demonstrates high blood-brain barrier permeability and possesses a notable antioxidant profile without neurotoxic effects. FAAH-IN-8 is valuable for research applications involving pain management, neuroinflammation, and cannabinoid modulation.

VDM11 is a potent and selective inhibitor of fatty acid amide hydrolase (FAAH), serving as a key modulator in endocannabinoid signaling. By inhibiting FAAH, VDM11 enhances the levels of anandamide, which can contribute to various physiological effects, including pain modulation and neuroprotection. This compound is beneficial for research applications examining endocannabinoid pathways and developing therapeutics for related disorders.

JNJ-40413269 is a potent inhibitor of fatty acid amide hydrolase (FAAH), demonstrating inhibition of human and rat FAAH with IC50 values of 28 nM and 270 nM, respectively. This compound exhibits notable analgesic efficacy in the rat spinal nerve ligation model, making it a valuable tool for pain research. Additionally, JNJ-40413269 showcases favorable pharmacokinetic properties in rats, supporting its potential utility in pharmaceutical development.

FAAH-IN-9 is an irreversible inhibitor of fatty acid amide hydrolase (FAAH) with a Ki value of 0.02 nM. This compound is specifically designed to enhance endocannabinoid signaling by preventing the degradation of endogenous fatty acid amides. FAAH-IN-9 is valuable for research into pain management, neuroprotection, and other physiological processes influenced by endocannabinoids.

MK-3168 (12C) is a potent FAAH inhibitor exhibiting IC50 values of 1.0 nM for human, 5.5 nM for rhesus, and 1.7 nM for rat models. This compound demonstrates significant brain uptake and produces a FAAH-specific signal, making it a valuable tool in neurobiological research. MK-3168 (12C) is also applicable as a PET tracer for studying FAAH activity in vivo, facilitating insights into cannabinoid signaling pathways.

CAY10435 is a β-ketooxazapyridine that selectively inhibits fatty acid amide hydrolase (FAAH). Demonstrating antimicrobial activity, CAY10435 binds non-competitively to FAAH in Dictyostelium discoideum with a dissociation constant (Kd) of 0.57 nM. This compound is valuable for studying FAAH-related pathways and exploring potential therapeutic applications targeting lipid signaling.

JNJ-42165279 dihydrochloride is a selective inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 70 nM for human FAAH and 313 nM for rat FAAH. This compound enhances endocannabinoid levels by preventing the breakdown of fatty acid amides, which can lead to increased pain relief and anti-inflammatory effects. JNJ-42165279 is utilized in research applications focusing on pain management, neuroprotection, and the modulation of the endocannabinoid system.

AZ513 is a reversible inhibitor of fatty acid amide hydrolase (FAAH), exhibiting IC50 values of 551 nM for human FAAH and 27 nM for rat FAAH. This compound effectively inhibits the hydrolysis of anandamide in human FAAH-transfected HEK293 cells, demonstrating an IC50 of 360 nM. AZ513 is suitable for research applications focusing on the modulation of endocannabinoid signaling pathways and the study of pain relief and neuroprotection mechanisms.

PHOP is a selective inhibitor of fatty acid amide hydrolase (FAAH), utilized in fluorometric assays to evaluate inhibitory activity. It effectively quantifies FAAH activity by detecting the release of 4-pyridin-1-ylbutyric acid in rat brain microsomes. PHOP's capability for direct measurement of FAAH activity through reversed-phase HPLC and fluorescence detection supports its potential as a foundational tool in the development of novel FAAH inhibitors. This reagent is instrumental in fatty acid signaling research and related therapeutic investigations.